New Developments in Active Surveillance for Prostate Cancer
In this peer-to-peer discussion, Dr. Loeb and Dr. Choyke discuss new developments in active surveillance for prostate cancer.
At the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 3–7 in Chicago, Stacy Loeb, MD, of the NYU Langone Medical Center in New York, New York, and Peter L. Choyke, MD, of the National Cancer Institute in Bethesda, Maryland, gave presentations during the education session “Contemporary Active Surveillance for Prostate Cancer: Do We Need Better Imaging and Molecular Testing?”
In this peer-to-peer discussion, Dr. Loeb and Dr. Choyke discuss some of the salient points from their session, including the use of magnetic resonance imaging for patient selection and follow-up and the use of new molecular markers that could signal tumor changes in patients on surveillance.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
